MX2023009064A - Derivado de pirimidina. - Google Patents
Derivado de pirimidina.Info
- Publication number
- MX2023009064A MX2023009064A MX2023009064A MX2023009064A MX2023009064A MX 2023009064 A MX2023009064 A MX 2023009064A MX 2023009064 A MX2023009064 A MX 2023009064A MX 2023009064 A MX2023009064 A MX 2023009064A MX 2023009064 A MX2023009064 A MX 2023009064A
- Authority
- MX
- Mexico
- Prior art keywords
- pyrimidine derivative
- compound
- mpges
- rheumatism
- inflammation
- Prior art date
Links
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 101710096361 Prostaglandin E synthase Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229910052731 fluorine Chemical group 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Abstract
Un compuesto de fórmula (I) o una sal del mismo (R representa un grupo metilo o un átomo de flúor) que tiene una actividad inhibidora de mPGES-1 y es útil como ingrediente activo de un medicamento para el tratamiento profiláctico y/o terapéutico de enfermedades tales como inflamación, dolor o reumatismo. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021015164 | 2021-02-02 | ||
| PCT/JP2022/003704 WO2022168808A1 (ja) | 2021-02-02 | 2022-02-01 | ピリミジン誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009064A true MX2023009064A (es) | 2023-08-14 |
Family
ID=82741402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009064A MX2023009064A (es) | 2021-02-02 | 2022-02-01 | Derivado de pirimidina. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240083867A1 (es) |
| EP (1) | EP4289832A1 (es) |
| JP (1) | JP7277676B2 (es) |
| KR (1) | KR20230142739A (es) |
| CN (1) | CN116867774A (es) |
| AU (1) | AU2022217610A1 (es) |
| CA (1) | CA3209656A1 (es) |
| IL (1) | IL304801A (es) |
| MX (1) | MX2023009064A (es) |
| TW (1) | TW202245776A (es) |
| WO (1) | WO2022168808A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024010015A1 (ja) * | 2022-07-06 | 2024-01-11 | あすか製薬株式会社 | ピリミジン誘導体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6310716Y2 (es) | 1979-06-19 | 1988-03-30 | ||
| HUE026671T2 (en) | 2011-08-18 | 2016-07-28 | Nippon Shinyaku Co Ltd | Heterocyclic derivatives as microsomal prostaglandin E synthetase inhibitors (mPGEs) |
| TWI568722B (zh) * | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| ES2616508T3 (es) * | 2013-03-04 | 2017-06-13 | Bayer Cropscience Aktiengesellschaft | Derivados de 1H-pirazol sustituidos con halógeno como insecticidas |
| WO2015059618A1 (en) | 2013-10-22 | 2015-04-30 | Glenmark Pharmaceuticals S.A. | SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| JP6817952B2 (ja) | 2015-10-29 | 2021-01-20 | あすか製薬株式会社 | ピリミジン誘導体 |
| WO2019044868A1 (ja) | 2017-08-30 | 2019-03-07 | あすか製薬株式会社 | ピリミジン誘導体 |
-
2022
- 2022-02-01 EP EP22749680.9A patent/EP4289832A1/en active Pending
- 2022-02-01 US US18/274,290 patent/US20240083867A1/en active Pending
- 2022-02-01 KR KR1020237028335A patent/KR20230142739A/ko unknown
- 2022-02-01 MX MX2023009064A patent/MX2023009064A/es unknown
- 2022-02-01 CN CN202280011568.6A patent/CN116867774A/zh active Pending
- 2022-02-01 CA CA3209656A patent/CA3209656A1/en active Pending
- 2022-02-01 JP JP2022579541A patent/JP7277676B2/ja active Active
- 2022-02-01 AU AU2022217610A patent/AU2022217610A1/en active Pending
- 2022-02-01 WO PCT/JP2022/003704 patent/WO2022168808A1/ja active Application Filing
- 2022-02-07 TW TW111104353A patent/TW202245776A/zh unknown
-
2023
- 2023-07-27 IL IL304801A patent/IL304801A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7277676B2 (ja) | 2023-05-19 |
| KR20230142739A (ko) | 2023-10-11 |
| IL304801A (en) | 2023-09-01 |
| CN116867774A (zh) | 2023-10-10 |
| JPWO2022168808A1 (es) | 2022-08-11 |
| EP4289832A1 (en) | 2023-12-13 |
| TW202245776A (zh) | 2022-12-01 |
| US20240083867A1 (en) | 2024-03-14 |
| WO2022168808A1 (ja) | 2022-08-11 |
| CA3209656A1 (en) | 2022-08-11 |
| AU2022217610A1 (en) | 2023-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551821A1 (en) | Novel compounds | |
| PH12021550310A1 (en) | Novel sulfonamideurea compounds | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2021007970A (es) | Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| EA202091016A1 (ru) | Пиримидиновое соединение в качестве ингибитора jak киназы | |
| MX2019012827A (es) | Derivados de tetrahidronaftilo urea novedosos. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2019013561A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| EA202091604A1 (ru) | Ингибирование ионного канала a1 с транзиторным рецепторным потенциалом | |
| ZA202204666B (en) | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
| CR20210630A (es) | Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| MX2023009064A (es) | Derivado de pirimidina. | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| MX2022015038A (es) | Compuestos heterociclicos como anthelminticos. | |
| MX2022010795A (es) | Hidrato cristalino de un compuesto inhibidor de jak. | |
| ZA202300912B (en) | Tyk-2 inhibitor | |
| WO2023073013A8 (en) | Lrrk2 inhibitors | |
| CR20220538A (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
| MX2021009971A (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende, metodo para su preparacion, y uso de estos. |